| Attribute |
Value |
| 52 Week Change |
-0.52030075 |
| Address1 |
P.O. BOX 125 |
| All Time High |
2,869.92 |
| All Time Low |
0.281 |
| Ask |
0.832 |
| Ask Size |
2 |
| Average Daily Volume10 Day |
1,778,560 |
| Average Daily Volume3 Month |
430,650 |
| Average Volume |
430,650 |
| Average Volume10Days |
1,778,560 |
| Beta |
2.006 |
| Bid |
0.4758 |
| Bid Size |
2 |
| Book Value |
0.739 |
| City |
Stewartsville |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
0.6579 |
| Current Ratio |
20.865 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
0.6919 |
| Day Low |
0.635 |
| Display Name |
VYNE Therapeutics |
| Earnings Timestamp End |
1,755,520,200 |
| Earnings Timestamp Start |
1,755,001,800 |
| Ebitda |
-24,345,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
0.123 |
| Enterprise To Revenue |
-6.575 |
| Enterprise Value |
-2,985,154 |
| Eps Current Year |
-1.1 |
| Eps Forward |
-1.65 |
| Eps Trailing Twelve Months |
-0.53 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,784,678,400 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
0.66114 |
| Fifty Day Average Change |
-0.003240049 |
| Fifty Day Average Change Percent |
-0.0049007 |
| Fifty Two Week Change Percent |
-52.030075 |
| Fifty Two Week High |
1.595 |
| Fifty Two Week High Change |
-0.93710005 |
| Fifty Two Week High Change Percent |
-0.5875235 |
| Fifty Two Week Low |
0.281 |
| Fifty Two Week Low Change |
0.3769 |
| Fifty Two Week Low Change Percent |
1.3412812 |
| Fifty Two Week Range |
0.281 - 1.595 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,516,890,600,000 |
| Float Shares |
30,544,547 |
| Forward Eps |
-1.65 |
| Forward P E |
-0.39872727 |
| Free Cashflow |
-20,400,000 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
10 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
1.0 |
| Gross Profits |
454,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.101160005 |
| Held Percent Institutions |
0.39581 |
| Implied Shares Outstanding |
33,385,055 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,676,246,400 |
| Last Split Factor |
1:18 |
| Long Business Summary |
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey. |
| Long Name |
VYNE Therapeutics Inc. |
| Market |
us_market |
| Market Cap |
21,964,028 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_6511914 |
| Most Recent Quarter |
1,774,915,200 |
| Name Change Date |
2,026-07-13 |
| Net Income To Common |
-21,718,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
21,286,311 |
| Open |
0.635 |
| Operating Cashflow |
-25,744,000 |
| Operating Margins |
-44.37209 |
| Payout Ratio |
0.0 |
| Phone |
800 775 7936 |
| Pre Market Change |
0.026600003 |
| Pre Market Change Percent |
4.043168 |
| Pre Market Price |
0.6845 |
| Pre Market Time |
1,784,016,020 |
| Prev Name |
Menlo Therapeutics Inc. |
| Previous Close |
0.6376 |
| Price Eps Current Year |
-0.5980909 |
| Price Hint |
4 |
| Price To Book |
0.89025706 |
| Price To Sales Trailing12 Months |
48.378918 |
| Profit Margins |
0.0 |
| Quick Ratio |
20.168 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
0.0203 |
| Regular Market Change Percent |
3.18381 |
| Regular Market Day High |
0.6919 |
| Regular Market Day Low |
0.635 |
| Regular Market Day Range |
0.635 - 0.6919 |
| Regular Market Open |
0.635 |
| Regular Market Previous Close |
0.6376 |
| Regular Market Price |
0.6579 |
| Regular Market Time |
1,783,972,800 |
| Regular Market Volume |
2,889,338 |
| Return On Assets |
-0.37013 |
| Return On Equity |
-0.63162 |
| Revenue Growth |
-0.574 |
| Revenue Per Share |
0.011 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
33,385,055 |
| Shares Percent Shares Out |
0.0031 |
| Shares Short |
104,336 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
120,420 |
| Short Name |
VYNE Therapeutics Inc. |
| Short Percent Of Float |
0.0032 |
| Short Ratio |
0.89 |
| Source Interval |
15 |
| State |
NJ |
| Symbol |
VYNE |
| Total Cash |
24,928,000 |
| Total Cash Per Share |
0.747 |
| Total Debt |
0 |
| Total Revenue |
454,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.53 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
0.540595 |
| Two Hundred Day Average Change |
0.11730498 |
| Two Hundred Day Average Change Percent |
0.21699235 |
| Type Disp |
Equity |
| Volume |
2,889,338 |
| Website |
https://vynetherapeutics.com |
| Zip |
8,886 |